Medicine by Design invests $1 million to advance bold new ideas in regenerative medicine
Seven funded projects poised to impact many diseases including cystic fibrosis, ALS and vision loss.
Meet our New Investigator: Omar F. Khan
Nanotechnology expert brings rich experience in academia and industry to the Institute of Biomedical Engineering.
Meet Medicine by Design’s 2020 Post-Doctoral Fellowship Award winners
Research to impact cancer, Alzheimer’s disease, autism, aneurysm and more.
Medicine by Design executive director profiled in Banting and Best Diabetes Centre story
The Banting and Best Diabetes Centre, University of Toronto (U of T), has published a profile honouring the work of Medicine by Design Executive Director Michael Sefton, who is also a University Professor at the Institute of Biomedical Engineering and the Department of Chemical Engineering & Applied Chemistry at the University of Toronto (U of T).
Medicine by Design seeds two strategic projects: An international partnership with the University of Cambridge and a new forum that will foster collaboration between clinicians, scientists and industry
$300,000 investment will accelerate new therapies and create new research tools.
Medicine by Design-funded researchers re-engineer enzyme that could help reverse damage from spinal cord injury and stroke
New version is more stable than the protein that occurs in nature, and could lead to new treatments for reversing nerve damage caused by traumatic injury or stroke.
Medicine by Design-funded researchers develop cell injection technique that could help reverse vision loss
The technique could point the way toward new treatments with the potential to reverse forms of vision loss that are currently incurable.
Critical planning for regenerative medicine therapies needs to happen now to ensure smooth adoption into health system, paper urges
Data generation, evidence of clinical effectiveness, cost and social values among the key considerations
Panel of Canadian regenerative medicine leaders tackle translation and commercialization challenges in panel discussion
How do trainees get started on a path toward developing a product or starting a company? What steps do researchers need to take to move their regenerative medicine discoveries from the lab toward clinical impact? These are just some of the questions an expert panel tackled on July 30 at a virtual event titled Translating Research to Impact – Leveraging Our Ecosystem.
U of T and SickKids researchers demonstrate drug stimulation of neural stem cell repair leads to promising impact on treatment of childhood brain injury in survivors of brain cancer
Cross-species study shows that Type 2 diabetes drug metformin could change the way childhood brain injury is treated
Medicine by Design’s Grand Questions Program aims to revolutionize regenerative medicine
$3 million investment to initiate answers to key questions that will transform health care
Medicine by Design-funded team uses stem cells to grow functional blood vessel cells found in the liver
Discovery to provide insights into liver development and disease progression
Medicine by Design launches Translation Talks
Weekly webinar series for trainees to cover key concepts in translation and commercialization of regenerative medicine.
Researchers delay onset of amyotrophic lateral sclerosis (ALS) in laboratory models
A team of researchers led by scientists at the University of Toronto has delayed the onset of amyotrophic lateral sclerosis (ALS) in mice. They are cautiously optimistic that this research, which was funded in part by a Medicine by Design 2018 New Ideas Award, combined with other clinical advances, points to a potential treatment for ALS in humans.
Medicine by Design supports coronavirus research through contribution to Toronto COVID-19 Action Fund
Thirty-one research projects at U of T and its affiliated hospitals selected for funding to contribute to the global fight against the novel coronavirus.